Navigating the Changing Landscape in AML: Key Considerations in Treatment Delivery

Welcome to the registration website for

Navigating the Changing Landscape in AML:
Key Considerations in Treatment Delivery

Join us for this webinar and earn
1.0 hour LIVE CME/CPE/CNE Credit.


Approximately 19,940 Americans will be
diagnosed with AML this year.

Are you up-to-date with the latest advances in diagnosis and treatment of AML?


Dr. Chetasi Talati Dr. Harry Erba Dr. Sandra Kurtin
Chetasi Talati, MD – Chair
Assistant Professor
Department of Oncologic Sciences
College of Medicine
University of South Florida
Tampa, Florida
Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Duke University
Durham, North Carolina
Sandra E. Kurtin, PhD, ANP-C, AOCN®
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor
of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Please join Dr. Talati, Dr. Erba and Dr. Kurtin as they discuss the newest questions and challenges you’re likely to face in your practice this year.

  • How do I select the appropriate induction treatment for my newly diagnosed AML patient?
  • My patient is diagnosed with secondary AML; does my treatment selection differ for these patients?
  • What about my patients who are 75 years old and older? Are there safety and/or efficacy concerns I should be aware of when selecting treatment?
  • Is my patient appropriate for induction therapy in the outpatient setting?
  • What are the key eligibility factors to consider in providing outpatient induction therapy?


20 min: Current and emerging treatment perspectives in AML in the newly diagnosed setting
  • Navigating the options for intensive and non-intensive induction therapy
  • Tailoring therapeutic choices to align with patient characteristics, risks, and patient goals
  • Safe and effective delivery of therapy: Is there a role for outpatient induction or consolidation chemotherapy? Insights and factors to consider
15 min: How do you select induction therapy for your patients? Interactive Case Presentations
10 min: Future perspectives and key considerations in outpatient care delivery: Discussions from a recent consensus meeting of experts in AML
15 min: Questions and Answers with the panel

Target Audience
This activity is designed for multidisciplinary healthcare providers including physicians, nurses, pharmacists, and other allied healthcare professionals who provide medical care to patients with acute myeloid leukemia.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Identify criteria by which patients should be assessed to determine eligibility for outpatient induction therapy
  • Describe a comprehensive clinical approach to monitoring and managing patients with AML who receive outpatient therapy
  • Examine the process for administration of intensive and less intensive induction and consolidation treatment in the outpatient setting for patients with either de novo or secondary AML
  • Summarize a patient-centered approach to care that is focused on patient/caregiver education


MediCom Worldwide, Inc. CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-002-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. Nursing Credit
MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-002-132

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures
Dr. Chetasi Talati has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company, speakers’ bureau activities from Astellas Pharma US, Inc. and Jazz Pharmaceuticals plc, as well as consultant fees from Daiichi Sankyo, Inc. and Pfizer Inc.

Dr. Harry Erba has received consultant fees from AbbVie Inc., Agios, Astellas Pharma US, Inc., Celgene Corporation – A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlycoMimetics, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, and Novartis AG, as well as honoraria related to speakers’ bureau activities from AbbVie, Agios, Celgene Corporation – A Bristol-Myers Squibb Company, Incyte, Jazz, and Novartis. He has received grant support related to research activities from AbbVie, Agios, Amgen Inc., Daiichi Sankyo, FORMA Therapeutics, Inc., Forty Seven Inc., GlycoMimetics, ImmunoGen, Inc., Jazz, MacroGenics, Inc., Novartis, and PTC Therapeutics.

Dr. Sandra Kurtin has received honoraria related to formal advisory activities and as a consultant from Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation - A Bristol-Myers Squibb Company, Incyte Corporation, Jazz Pharmaceuticals plc, Novartis AG, Pharmacyclics, Inc., and Takeda Oncology.

Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Instructions for Participation and Credit
There are no fees for participating in this activity.

In order to receive credit, all participants must complete the self-assessment post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or

Provided by
MediCom Worldwide, Inc.

Supported by an educational grant from Jazz Pharmaceuticals.


Navigating the Changing Landscape in AML: Key Considerations in Treatment Delivery